Literature DB >> 7376042

Adverse effect of radiotherapy on adjuvant chemotherapy for carcinoma of the breast.

J F Holland, O Glidewell, R G Cooper.   

Abstract

Twenty-seven women with primary carcinoma of the breast with greater than or equal to 4 metastatic axillary nodes received prophylactic radiotherapy in addition to adjuvant vincristine, prednisone, cyclophosphamide, methotrexate and fluorouracil chemotherapy. When compared with 73 women who received chemotherapy alone, the relapse rate per month for the patients with radiation therapy was fourfold greater, p = less than 0.0001. Recurrence in 17 of 27 contrasts with relapse in 13 of 73 patients who did not undergo irradiation. By eight years, 14 of 27 patients who received radiotherapy had died, contrasted with nine of 73 who received chemotherapy alone. The results for the irradiated subset were found not to be due to patient selection nor to shortening or underdosing of chemotherapy. Immunosuppression from radiation and systematic delay in initiating chemotherapy remain among the possible explanations. These data support the use of adjuvant chemotherapy and argue against the prophylactic use of radiotherapy following mastectomy for carcinoma of the breast.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7376042

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  4 in total

1.  Adjuvant chemotherapy of breast cancer: hope--reality--hazard?

Authors:  H Vorherr
Journal:  Klin Wochenschr       Date:  1984-02-15

Review 2.  Update on cancer chemotherapy: general considerations and breast cancer. Part II.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1985-09       Impact factor: 1.798

Review 3.  Chemotherapy of breast cancer.

Authors:  L S Perlow; J F Holland
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

4.  Feasibility of a dose-intensive CMF regimen with granulocyte colony-stimulating factor as adjuvant therapy in premenopausal patients with node-positive breast cancer.

Authors:  A M Bos; H de Graaf; E G de Vries; H Piersma; P H Willemse
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.